ALK-Abelló Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St · 02/21 04:42

ALK-Abelló (CPH:ALK B) Full Year 2024 Results

Key Financial Results

  • Revenue: kr.5.54b (up 15% from FY 2023).
  • Net income: kr.815.0m (up 68% from FY 2023).
  • Profit margin: 15% (up from 10% in FY 2023). The increase in margin was driven by higher revenue.
  • EPS: kr.3.68 (up from kr.2.20 in FY 2023).

ALK B Products In Clinical Trials

  • Phase II: 2.
  • Phase III: 3.

ALK B Post-Clinical Trial Products

  • Pre-registration: 3.
revenue-and-expenses-breakdown
CPSE:ALK B Revenue and Expenses Breakdown February 21st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

ALK-Abelló EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.9%.

The primary driver behind last 12 months revenue was the Other Europe segment contributing a total revenue of kr.1.45b (26% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to kr.1.56b (57% of total expenses). Explore how ALK B's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Denmark.

The company's shares are down 2.0% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on ALK-Abelló's balance sheet health.